{"id":"amisulpride-moclobemide","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Parkinsonism"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Hypertension (moclobemide-related)"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL86304","moleculeType":"Small molecule","molecularWeight":"268.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amisulpride selectively blocks dopamine D2 and D3 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms and improving negative symptoms of schizophrenia. Moclobemide inhibits monoamine oxidase-A, increasing serotonin and noradrenaline availability, which enhances mood and reduces depressive symptoms. The combination targets both dopaminergic and monoaminergic systems to address multiple psychiatric symptom domains.","oneSentence":"This combination uses amisulpride (a dopamine D2/D3 antagonist) and moclobemide (a reversible monoamine oxidase-A inhibitor) to modulate dopaminergic and monoaminergic neurotransmission for psychiatric symptom management.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:13.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia with depressive symptoms"},{"name":"Schizoaffective disorder"}]},"trialDetails":[{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00534573","phase":"PHASE3","title":"Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation","status":"COMPLETED","sponsor":"Beersheva Mental Health Center","startDate":"2008-11","conditions":"Clozapine-induced Hypersalivation","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Amisulpride, Moclobemide","genericName":"Amisulpride, Moclobemide","companyName":"Beersheva Mental Health Center","companyId":"beersheva-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses amisulpride (a dopamine D2/D3 antagonist) and moclobemide (a reversible monoamine oxidase-A inhibitor) to modulate dopaminergic and monoaminergic neurotransmission for psychiatric symptom management. Used for Schizophrenia with depressive symptoms, Schizoaffective disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}